TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $12.50.

A number of brokerages have issued reports on TLSI. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday. They set an "outperform" rating and a $12.50 price objective on the stock. Oppenheimer assumed coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an "outperform" rating and a $10.00 price target on the stock. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday.

TriSalus Life Sciences Trading Down 1.0 %

Shares of TLSI stock traded down $0.04 on Friday, reaching $4.07. The company's stock had a trading volume of 8,510 shares, compared to its average volume of 38,954. The stock's fifty day simple moving average is $4.70 and its 200-day simple moving average is $6.39. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.42. The company has a market capitalization of $119.29 million, a price-to-earnings ratio of -1.63 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $7.36 million for the quarter. Equities research analysts forecast that TriSalus Life Sciences will post -1.53 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction dated Thursday, September 12th. The stock was purchased at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the purchase, the chief executive officer now owns 377,382 shares of the company's stock, valued at $1,962,386.40. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 32.80% of the company's stock.

Institutional Trading of TriSalus Life Sciences

A number of large investors have recently modified their holdings of the company. Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth $240,000. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences in the second quarter worth about $1,184,000. Finally, Duquesne Family Office LLC grew its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock worth $2,357,000 after acquiring an additional 110,966 shares in the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.